三友医疗：发布2025年业绩快报，业绩符合预期，接近预告区间中位数 2025年公司实现收入5.43亿元（业绩预告5.35亿元-5.62亿元），同比增长19.66%；实现归母净利润0.63亿元（业绩 预告0.56亿元-0.73亿元），同比增长451.85%；实现扣非归母净利润0.50亿元（业绩预告0.43亿元-0.61亿元），同 比实现扭亏为盈。 据此计算，2025Q4收入约1.51亿元（+25 三友医疗：发布2025年业绩快报，业绩符合预期，接近预告区间中位数 2025年公司实现收入5.43亿元（业绩预告5.35亿元-5.62亿元），同比增长19.66%；实现归母净利润0.63亿元（业绩 预告0.56亿元-0.73亿元），同比增长451.85%；实现扣非归母净利润0.50亿元（业绩预告0.43亿元-0.61亿元），同 比实现扭亏为盈。 据此计算，2025Q4收入约1.51亿元（+25%），归母净利润约131万元（-52%），扣非归母净利润约32万元，上年 同期为-647万元。 业绩变化主要原因： 1）2025年公司在带量采购全面执行的压力下，利用自身创新疗法优势，不断进行新产品的开发和合作，进一步丰 富和增加 ...

Core Viewpoint - Shanghai Sanyou Medical Instrument Co., Ltd. anticipates significant growth in its 2025 financial performance, with projected increases in both revenue and net profit compared to the previous year [1][2]. Financial Performance Forecast - The company expects its annual revenue for 2025 to be between 535 million yuan and 562 million yuan, representing an increase of 81.4 million yuan to 108.4 million yuan, or a year-on-year growth of 17.95% to 23.90% [1]. - The projected net profit attributable to shareholders for 2025 is estimated to be between 56 million yuan and 72.8 million yuan, indicating an increase of 44.53 million yuan to 61.33 million yuan, with a year-on-year growth of 388.29% to 534.78% [1][2]. - The net profit after deducting non-recurring gains and losses is expected to be between 43 million yuan and 61 million yuan, marking a turnaround from a loss in the previous year [2]. Previous Year Performance - In 2024, the company reported a revenue of 453.60 million yuan, a total profit of 21.90 million yuan, and a net profit attributable to shareholders of 11.47 million yuan. The net profit after deducting non-recurring gains and losses was a loss of 3.78 million yuan, with earnings per share of 0.05 yuan [4]. Reasons for Performance Change - The company has leveraged its innovative therapy advantages to develop new products and expand its product line, which has contributed to stable sales growth in the orthopedic industry [5]. - The ultrasound knife business has seen rapid growth in both sales and net profit, while international business continues to expand, with the subsidiary Implanet achieving a revenue of 12.47 million euros, a year-on-year increase of 32.62% [5]. - The company is focused on therapy innovation and market expansion, aiming to obtain regulatory approvals for new products and enhance market penetration of existing products [6][7]. Strategic Initiatives - The company plans to promote its ultrasound knife business and other integrated product lines in various medical fields, while also pushing for the sales growth of international products in the Chinese market [6][7]. - A stock incentive plan will be introduced in 2025, with an estimated share-based payment expense of approximately 8.4 million yuan [7].

Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a range of 56 million to 72.8 million yuan, representing a year-on-year growth of 388.29% to 534.78% [1] Financial Projections - The projected net profit attributable to shareholders for 2025 is between 56 million and 72.8 million yuan, with a non-GAAP net profit forecasted at 43 million to 61 million yuan, indicating a turnaround from losses [1] - The company anticipates a total of approximately 30 million yuan in asset impairment and credit impairment losses for the year [1] Business Strategy and Growth - The company plans to leverage its innovative therapies and expand its product line to enhance sales and market penetration, particularly in the orthopedic sector, where it is a leading player [1] - The ultrasound knife business is expected to see rapid growth in both sales and net profit in 2025 [1] - The international business, particularly through its subsidiary Implanet, is projected to achieve revenue of 1,247.39 million euros, a year-on-year increase of 32.62%, with the U.S. market showing a remarkable growth of 49.30% [1] Product Development and Market Expansion - The company aims to expedite the registration of innovative products such as the intelligent surgical robot and porous polyether ether ketone interbody fusion device in China [1] - There is a focus on increasing the penetration of the ultrasound knife business and promoting integrated product series in various surgical departments [1] - The company is committed to advancing its strategic business layout and ensuring the timely approval of its innovative products in the U.S. market by 2026 [1] Equity Incentive Plan - The company will introduce an equity incentive plan in 2025, with an estimated share-based payment expense of approximately 8.4 million yuan for the year [1]